Tag Archive for: Antibody-drug conjugate

SOTIO Enters Licensing Agreement With Synaffix to Expand ADC Pipeline

Synaffix to provide access to proprietary Antibody-Drug Conjugate (ADC) technologies  SOTIO to develop up to three next generation bioconjugates  Total potential deal value of up to $740 million, plus royalties on commercial sales for three ADC programs  AMSTERDAM, THE NETHERLANDS, 16 September 2023 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage […]

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program

Amsterdam and San Francisco / Houston / Singapore, 4 January 2023 — Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, and Hummingbird Bioscience (Hummingbird Bio), a data-driven precision biotherapeutics company using its Rational Antibody Discovery (RAD) platform to discover and […]

Genmab and Synaffix Enter into License Agreement for ADC Technology

Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapies Synaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus […]